Welcome to our dedicated page for Atmofizer Techno news (Ticker: ATMFF), a resource for investors and traders seeking the latest updates and insights on Atmofizer Techno stock.
The Atmofizer Technologies Inc. (ATMFF) news page on Stock Titan aggregates company announcements, press releases and market updates related to its air purification and ultrafine particle control business. Atmofizer operates in the pollution and treatment controls sector, focusing on patent-protected and patent-pending technology for ultrafine particle agglomeration and neutralization in consumer, industrial and HVAC applications.
News items for Atmofizer often cover technology developments, such as third-party laboratory testing of its airborne nanoparticle agglomeration engine and performance data for its Atmofizer ONE devices. The company has reported results showing reductions in specific microorganisms and changes in particle size distributions, and it has discussed how these findings support its approach to air treatment using ultrasonic acoustic waves and ultraviolet light.
Investors and observers can also find updates on intellectual property milestones, including U.S. patents and Notices of Allowance for applications like "Ultra-Fine Particle Aggregation, Neutralization and Filtration," as well as communications about how Atmofizer plans to license its technology to air purification device manufacturers and HVAC suppliers. Corporate developments, such as the establishment of an at-the-market equity program, share consolidation actions and distribution or partnership arrangements, are also reflected in the company’s news flow.
Another recurring theme in Atmofizer’s news is its focus on the HVAC market, where it is working to integrate its agglomeration technology into existing forced air systems and to collaborate with HVAC service providers. In addition, the company has issued announcements regarding a proposed business combination with House of Doge Inc. and a subsequent mutual termination of that agreement. By reviewing this news stream, readers can follow Atmofizer’s progress in technology validation, licensing efforts, capital markets activity and strategic initiatives. Bookmark this page to access a consolidated view of Atmofizer’s disclosed developments over time.
Atmofizer Technologies Inc. (CSE: ATMO; OTCQB: ATMFF) has announced significant advancements with its agglomeration technology, which effectively reduces ultrafine nanoparticle counts by 44% at a rate of 1.4 liters per minute. This patented method enhances air quality by allowing for safer neutralization of harmful particles. Additionally, Atmofizer has opened a new R&D lab in Toronto aimed at innovating HVAC systems and further testing their technology in practical settings. This initiative could lead to new partnerships and markets if successful.
Atmofizer Technologies Inc. (OTCQB: ATMFF) reported financial results for the year ending December 31, 2021, revealing a revenue of $497,280 and a net loss of $21.43 million, compared to a loss of $1.17 million in 2020. The notable increase in expenses, totaling $13.18 million, was primarily due to operational expansion and a listing expense of $7.09 million linked to a reverse takeover. Despite a gross profit of $83,199 (16.7%), overall financial performance raised concerns among investors, driven by significant net losses and high operational costs.
Atmofizer Technologies has established an internal R&D lab in Toronto to advance its nanoparticle agglomeration technology for HVAC systems. The innovative technology aims to enhance air quality by increasing particle sizes for better filtration, which can lower energy costs and extend filter life. Recent tests indicate a 44% reduction in ultrafine particle counts, potentially benefiting residential and commercial HVAC systems. Atmofizer has delivered around 2,000 agglomeration engines globally and anticipates further demand from various sectors, including maritime and aviation.
Atmofizer Technologies Inc. has announced the issuance of a key patent from the USPTO for its air and water purification technology, titled Ultra-Fine Particle Aggregation, Neutralization and Filtration. This patent not only protects their intellectual property but also validates their approach to improving indoor air quality, especially in light of COVID-19. Furthermore, Atmofizer has entered into a Debt Settlement Agreement, issuing 2,500,000 shares at $0.09 each to settle $225,000 in debt. This strategic move is aimed at enhancing their market position as leaders in air purification technology.
Atmofizer Technologies Inc. (CSE: ATMO, OTCQB: ATMFF) has launched an internal R&D lab in Toronto to innovate HVAC systems using its nanoparticle agglomeration technology. This technology aims to enhance air quality and reduce energy costs by increasing the size of harmful particles, making them easier to neutralize with UV light and conventional filters. Initial tests show a 44% reduction in ultrafine particles, potentially leading to lower operational costs and improved filter efficiency, thereby benefiting both consumers and the environment.
Atmofizer Technologies Inc. has introduced a patented air and water purification technology aimed at combating airborne viruses and pollution. The system utilizes a unique method of agglomeration to cluster nano-scale particles, making them easier to neutralize. This innovation is timely, given the increased focus on air quality post-COVID-19. The company plans to license its technology to various industries, enhancing air safety and reducing operational costs. Independent data supports its efficacy in reducing harmful particles.
Atmofizer Technologies Inc. announced that the USPTO issued a notice of allowance for its air and water purification technology patent, US Patent Application No. 17/471,610. This patent provides broad protection for Atmofizer's innovative technology aimed at purifying ultra-fine particles, enhancing air quality, and potentially disrupting the air treatment market. CEO Olivier Centner highlighted the importance of this patent in addressing air safety amid growing market demand. The patent is expected to be officially issued soon, providing a strategic advantage for Atmofizer's commercialization efforts.